Publications
-
Hypocretin/orexin and narcolepsy: new basic and clinical insights.
Nishino S,
Okuro M, Kotorii N, Anegawa E, Ishimaru Y, Matsumura M, Kanbayashi T.
Acta Physiol (Oxf).
2010;
198
(3):
209-22
-
Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle.
Kang JE,
Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM.
Science.
2009;
326
(5955):
1005-7
-
CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome.
Kanbayashi T,
Kodama T, Kondo H, Satoh S, Inoue Y, Chiba S, Shimizu T, Nishino S.
Sleep.
2009;
32
(2):
181-7
-
Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls.
Nishino S,
Sakurai E, Nevsimalova S, Yoshida Y, Watanabe T, Yanai K, Mignot E.
Sleep.
2009;
32
(2):
175-80
-
Orexin neurons are necessary for the circadian control of REM sleep.
Kantor S,
Mochizuki T, Janisiewicz AM, Clark E, Nishino S, Scammell TE.
Sleep.
2009;
32
(9):
1127-34
-
Specificity of direct transition from wake to REM sleep in orexin/ataxin-3 transgenic narcoleptic mice.
Fujiki N,
Cheng T, Yoshino F, Nishino S.
Exp Neurol.
2009;
217
(1):
46-54
-
The transcriptional repressor DEC2 regulates sleep length in mammals.
He Y,
Jones CR, Fujiki N, Xu Y, Guo B, Holder JL, Rossner MJ, Nishino S, Fu YH.
Science.
2009;
325
(5942):
866-70
-
Armodafinil for excessive daytime sleepiness.
Nishino S,
Okuro M.
Drugs Today (Barc).
2008;
44
(6):
395-414
-
CSF histamine levels in rats reflect the central histamine neurotransmission.
Soya A,
Song YH, Kodama T, Honda Y, Fujiki N, Nishino S.
Neurosci Lett.
2008;
430
(3):
224-9
-
Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy.
Mishima K,
Fujiki N, Yoshida Y, Sakurai T, Honda M, Mignot E, Nishino S.
Sleep.
2008;
31
(8):
1119-26
-
Sleep and EEG features in genetic models of Down syndrome.
Colas D,
Valletta JS, Takimoto-Kimura R, Nishino S, Fujiki N, Mobley WC, Mignot E.
Neurobiol Dis.
2008;
30
(1):
1-7
-
[The US Government's effort in decreasing the cost of sleep-related problems and its outcome].
Song YH,
Nishino S.
J UOEH.
2008;
30
(3):
329-52
-
Clinical and neurobiological aspects of narcolepsy.
Nishino S,
Sleep Med.
2007;
8
(4):
373-99
-
Narcolepsy: pathophysiology and pharmacology.
Nishino S,
J Clin Psychiatry.
2007:
68 Suppl 13
9-15
-
Neuropeptides as possible targets in sleep disorders.
Nishino S,
Fujiki N.
Expert Opin Ther Targets.
2007;
11
(1):
37-59
-
Neuropeptides as possible targets in sleep disorders: special emphasis on hypocretin-deficient narcolepsy.
Fujiki N,
Nishino S.
CNS Neurol Disord Drug Targets.
2007;
6
(1):
45-62
-
Sleep/wake fragmentation disrupts metabolism in a mouse model of narcolepsy.
Zhang S,
Zeitzer JM, Sakurai T, Nishino S, Mignot E.
J Physiol.
2007;
581
(Pt 2):
649-63
-
The hypocretin/orexin receptor: therapeutic prospective in sleep disorders.
Nishino S,
Expert Opin Investig Drugs.
2007;
16
(11):
1785-97
-
The hypothalamic peptidergic system, hypocretin/orexin and vigilance control.
Nishino S,
Neuropeptides.
2007;
41
(3):
117-33
-
Addiction and arousal: alternative roles of hypothalamic peptides.
de Lecea L,
Jones BE, Boutrel B, Borgland SL, Nishino S, Bubser M, DiLeone R.
J Neurosci.
2006;
26
(41):
10372-5
-
An activation of parvocellular oxytocinergic neurons in the paraventricular nucleus in oxytocin-induced yawning and penile erection.
Kita I,
Yoshida Y, Nishino S.
Neurosci Res.
2006;
54
(4):
269-75
-
CSF versus serum leptin in narcolepsy: is there an effect of hypocretin deficiency?
Arnulf I,
Lin L, Zhang J, Russell IJ, Ripley B, Einen M, Nevsimalova S, Bassetti C, Bourgin P, Nishino S, Mignot E.
Sleep.
2006;
29
(8):
1017-24
-
Sex difference in body weight gain and leptin signaling in hypocretin/orexin deficient mouse models.
Fujiki N,
Yoshida Y, Zhang S, Sakurai T, Yanagisawa M, Nishino S.
Peptides.
2006;
27
(9):
2326-31
-
The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions.
Zeitzer JM,
Nishino S, Mignot E.
Trends Pharmacol Sci.
2006;
27
(7):
368-74
-
Conditions of primary excessive daytime sleepiness.
Black JE,
Brooks SN, Nishino S.
Neurol Clin.
2005;
23
(4):
1025-44
-
Emerging therapies in narcolepsy-cataplexy.
Mignot E,
Nishino S.
Sleep.
2005;
28
(6):
754-63
-
Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system.
Nishino S,
Kanbayashi T.
Sleep Med Rev.
2005;
9
(4):
269-310
-
Lesions of the suprachiasmatic nucleus eliminate the daily rhythm of hypocretin-1 release.
Zhang S,
Zeitzer JM, Yoshida Y, Wisor JP, Nishino S, Edgar DM, Mignot E.
Sleep.
2004;
27
(4):
619-27
-
Narcolepsy and syndromes of primary excessive daytime somnolence.
Black JE,
Brooks SN, Nishino S.
Semin Neurol.
2004;
24
(3):
271-82
-
The roles of midbrain and diencephalic dopamine cell groups in the regulation of cataplexy in narcoleptic Dobermans.
Okura M,
Fujiki N, Kita I, Honda K, Yoshida Y, Mignot E, Nishino S.
Neurobiol Dis.
2004;
16
(1):
274-82
-
CSF hypocretin levels in Guillain-Barré syndrome and other inflammatory neuropathies.
Nishino S,
Kanbayashi T, Fujiki N, Uchino M, Ripley B, Watanabe M, Lammers GJ, Ishiguro H, Shoji S, Nishida Y, Overeem S, Toyoshima I, Yoshida Y, Shimizu T, Taheri S, Mignot E.
Neurology.
2003;
61
(6):
823-5
-
Differential kinetics of hypocretins in the cerebrospinal fluid after intracerebroventricular administration in rats.
Yoshida Y,
Fujiki N, Maki RA, Schwarz D, Nishino S.
Neurosci Lett.
2003;
346
(3):
182-6
-
Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog.
Fujiki N,
Yoshida Y, Ripley B, Mignot E, Nishino S.
Sleep.
2003;
26
(8):
953-9
-
The hypocretin/orexin system in health and disease.
Nishino S,
Biol Psychiatry.
2003;
54
(2):
87-95
-
Analysis of onset location, laterality and propagation of cataplexy in canine narcolepsy.
Fujiki N,
Morris L, Mignot E, Nishino S.
Psychiatry Clin Neurosci.
2002;
56
(3):
275-6
-
Article reviewed: Plasma orexin-A is lower in patients with narcolepsy.
Nishino S,
Mignot E.
Sleep Med.
2002;
3
(4):
377-8
-
CSF hypocretin-1 levels in schizophrenics and controls: relationship to sleep architecture.
Nishino S,
Ripley B, Mignot E, Benson KL, Zarcone VP.
Psychiatry Res.
2002;
110
(1):
1-7
-
Hypocretin stimulates [(35)S]GTP gamma S binding in Hcrtr 2-transfected cell lines and in brain homogenate.
Shiba T,
Ozu M, Yoshida Y, Mignot E, Nishino S.
Biochem Biophys Res Commun.
2002;
294
(3):
615-20
-
Measurement of hypocretin/orexin content in the mouse brain using an enzyme immunoassay: the effect of circadian time, age and genetic background.
Lin L,
Wisor J, Shiba T, Taheri S, Yanai K, Wurts S, Lin X, Vitaterna M, Takahashi J, Lovenberg TW, Koehl M, Uhl G, Nishino S, Mignot E.
Peptides.
2002;
23
(12):
2203-11
-
Sleeping with the hypothalamus: emerging therapeutic targets for sleep disorders.
Mignot E,
Taheri S, Nishino S.
Nat Neurosci.
2002:
5 Suppl
1071-5
-
The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.
Mignot E,
Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, Vankova J, Black J, Harsh J, Bassetti C, Schrader H, Nishino S.
Arch Neurol.
2002;
59
(10):
1553-62
-
CSF hypocretin/orexin levels in narcolepsy and other neurological conditions.
Ripley B,
Overeem S, Fujiki N, Nevsimalova S, Uchino M, Yesavage J, Di Monte D, Dohi K, Melberg A, Lammers GJ, Nishida Y, Roelandse FW, Hungs M, Mignot E, Nishino S.
Neurology.
2001;
57
(12):
2253-8
-
Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and in response to food deprivation.
Fujiki N,
Yoshida Y, Ripley B, Honda K, Mignot E, Nishino S.
Neuroreport.
2001;
12
(5):
993-7
-
Decreased brain histamine content in hypocretin/orexin receptor-2 mutated narcoleptic dogs.
Nishino S,
Fujiki N, Ripley B, Sakurai E, Kato M, Watanabe T, Mignot E, Yanai K.
Neurosci Lett.
2001;
313
(3):
125-8
-
Dopaminergic role in stimulant-induced wakefulness.
Wisor JP,
Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM.
J Neurosci.
2001;
21
(5):
1787-94
-
Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities.
Yoshida Y,
Fujiki N, Nakajima T, Ripley B, Matsumura H, Yoneda H, Mignot E, Nishino S.
Eur J Neurosci.
2001;
14
(7):
1075-81
-
Hypocretin levels in sporadic and familial cases of canine narcolepsy.
Ripley B,
Fujiki N, Okura M, Mignot E, Nishino S.
Neurobiol Dis.
2001;
8
(3):
525-34
-
Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy.
Nishino S,
Ripley B, Overeem S, Nevsimalova S, Lammers GJ, Vankova J, Okun M, Rogers W, Brooks S, Mignot E.
Ann Neurol.
2001;
50
(3):
381-8
-
Narcoleptic canines display periodic leg movements during sleep.
Okura M,
Fujiki N, Ripley B, Takahashi S, Amitai N, Mignot E, Nishino S.
Psychiatry Clin Neurosci.
2001;
55
(3):
243-4
-
A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.
Peyron C,
Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, Nevsimalova S, Aldrich M, Reynolds D, Albin R, Li R, Hungs M, Pedrazzoli M, Padigaru M, Kucherlapati M, Fan J, Maki R, Lammers GJ, Bouras C, Kucherlapati R, Nishino S, Mignot E.
Nat Med.
2000;
6
(9):
991-7
-
Chronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsy.
Riehl J,
Honda K, Kwan M, Hong J, Mignot E, Nishino S.
Neuropsychopharmacology.
2000;
23
(1):
34-45
-
Implication of dopaminergic mechanisms in the wake-promoting effects of amphetamine: a study of D- and L-derivatives in canine narcolepsy.
Kanbayashi T,
Honda K, Kodama T, Mignot E, Nishino S.
Neuroscience.
2000;
99
(4):
651-9
-
Inheritance of von Willebrand's disease in a colony of Doberman Pinschers.
Riehl J,
Okura M, Mignot E, Nishino S.
Am J Vet Res.
2000;
61
(2):
115-20
-
Is narcolepsy a REM sleep disorder? Analysis of sleep abnormalities in narcoleptic Dobermans.
Nishino S,
Riehl J, Hong J, Kwan M, Reid M, Mignot E.
Neurosci Res.
2000;
38
(4):
437-46
-
Narcolepsy: genetic predisposition and neuropharmacological mechanisms. REVIEW ARTICLE.
Nishino S,
Okura M, Mignot E.
Sleep Med Rev.
2000;
4
(1):
57-99
-
Sulpiride, a D2/D3 blocker, reduces cataplexy but not REM sleep in canine narcolepsy.
Okura M,
Riehl J, Mignot E, Nishino S.
Neuropsychopharmacology.
2000;
23
(5):
528-38
-
Dopamine D3 agonists into the substantia nigra aggravate cataplexy but do not modify sleep [corrected].
Honda K,
Riehl J, Mignot E, Nishino S.
Neuroreport.
1999;
10
(14):
3111-8
-
Dopamine D3 agonists into the substantia nigra aggravate cataplexy but do not modify sleep.
Honda K,
Riehl J, Mignot E, Nishino S.
Neuroreport.
1999;
10
(17):
3717-24
-
Drug treatment of patients with insomnia and excessive daytime sleepiness: pharmacokinetic considerations.
Nishino S,
Mignot E.
Clin Pharmacokinet.
1999;
37
(4):
305-30
-
The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene.
Lin L,
Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong PJ, Nishino S, Mignot E.
Cell.
1999;
98
(3):
365-76
-
Breeding history of the Stanford colony of narcoleptic dogs.
Cederberg R,
Nishino S, Dement WC, Mignot E.
Vet Rec.
1998;
142
(2):
31-6
-
Cerebrospinal fluid prostaglandins and corticotropin releasing factor in schizophrenics and controls: relationship to sleep architecture.
Nishino S,
Mignot E, Benson KL, Zarcone VP.
Psychiatry Res.
1998;
78
(3):
141-50
-
Development of cataplexy in genetically narcoleptic Dobermans.
Riehl J,
Nishino S, Cederberg R, Dement WC, Mignot E.
Exp Neurol.
1998;
152
(2):
292-302
-
Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants.
Nishino S,
Mao J, Sampathkumaran R, Shelton J.
Sleep Res Online.
1998;
1
(1):
49-61
-
Neuronal activity in the cholinoceptive basal forebrain of freely moving narcoleptic dobermans.
Nishino S,
Honda K, Riehl J, Okura M, Mignot E.
Neuroreport.
1998;
9
(16):
3653-61
-
Neuropharmacological characterization of basal forebrain cholinergic stimulated cataplexy in narcoleptic canines.
Reid MS,
Nishino S, Tafti M, Siegel JM, Dement WC, Mignot E.
Exp Neurol.
1998;
151
(1):
89-104
-
Central administration of vitamin B12 aggravates cataplexy in canine narcolepsy.
Honda K,
Riehl J, Inoué S, Mignot E, Nishino S.
Neuroreport.
1997;
8
(18):
3861-5
-
Circadian distribution of rest/activity in narcoleptic and control dogs: assessment with ambulatory activity monitoring.
Nishino S,
Tafti M, Sampathkumaran R, Dement WC, Mignot E.
J Sleep Res.
1997;
6
(2):
120-7
-
Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy.
Nishino S,
Arrigoni J, Shelton J, Kanbayashi T, Dement WC, Mignot E.
J Neurosci.
1997;
17
(16):
6401-8
-
Mesopontine organization of cholinergic and catecholaminergic cell groups in the normal and narcoleptic dog.
Tafti M,
Nishino S, Liao W, Dement WC, Mignot E.
J Comp Neurol.
1997;
379
(2):
185-97
-
Pharmacological aspects of human and canine narcolepsy.
Nishino S,
Mignot E.
Prog Neurobiol.
1997;
52
(1):
27-78
-
Major histocompatibility class II molecules in the CNS: increased microglial expression at the onset of narcolepsy in canine model.
Tafti M,
Nishino S, Aldrich MS, Liao W, Dement WC, Mignot E.
J Neurosci.
1996;
16
(15):
4588-95
-
Thalidomide, a hypnotic with immune modulating properties, increases cataplexy in canine narcolepsy.
Kanbayashi T,
Nishino S, Tafti M, Hishikawa Y, Dement WC, Mignot E.
Neuroreport.
1996;
7
(12):
1881-6
-
Thalidomide, immune modulation and narcolepsy.
Kanbayashi T,
Nishino S, Tafti M, Hishikawa Y, Dement WC, Mignot E.
Sleep.
1996;
19
(2):
116
-
Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs.
Shelton J,
Nishino S, Vaught J, Dement WC, Mignot E.
Sleep.
1995;
18
(10):
817-26
-
Effect of 5-HT1A receptor agonists and antagonists on canine cataplexy.
Nishino S,
Shelton J, Renaud A, Dement WC, Mignot E.
J Pharmacol Exp Ther.
1995;
272
(3):
1170-5
-
Muscle atonia is triggered by cholinergic stimulation of the basal forebrain: implication for the pathophysiology of canine narcolepsy.
Nishino S,
Tafti M, Reid MS, Shelton J, Siegel JM, Dement WC, Mignot E.
J Neurosci.
1995;
15
(7 Pt 1):
4806-14
-
Cholinergic mechanisms in canine narcolepsy--I. Modulation of cataplexy via local drug administration into the pontine reticular formation.
Reid MS,
Tafti M, Geary JN, Nishino S, Siegel JM, Dement WC, Mignot E.
Neuroscience.
1994;
59
(3):
511-22
-
Cholinergic regulation of cataplexy in canine narcolepsy in the pontine reticular formation is mediated by M2 muscarinic receptors.
Reid MS,
Tafti M, Nishino S, Siegel JM, Dement WC, Mignot E.
Sleep.
1994;
17
(5):
424-35
-
Modafinil binds to the dopamine uptake carrier site with low affinity.
Mignot E,
Nishino S, Guilleminault C, Dement WC.
Sleep.
1994;
17
(5):
436-7
-
Neuropharmacology and neurochemistry of canine narcolepsy.
Nishino S,
Reid MS, Dement WC, Mignot E.
Sleep.
1994;
17
(8 Suppl):
S84-92
-
Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers.
Mignot E,
Renaud A, Nishino S, Arrigoni J, Guilleminault C, Dement WC.
Psychopharmacology (Berl).
1993;
113
(1):
76-82
-
Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds.
Nishino S,
Arrigoni J, Shelton J, Dement WC, Mignot E.
Sleep.
1993;
16
(8):
706-12
-
Further characterization of the alpha-1 receptor subtype involved in the control of cataplexy in canine narcolepsy.
Nishino S,
Fruhstorfer B, Arrigoni J, Guilleminault C, Dement WC, Mignot E.
J Pharmacol Exp Ther.
1993;
264
(3):
1079-84
-
Heterozygosity at the canarc-1 locus can confer susceptibility for narcolepsy: induction of cataplexy in heterozygous asymptomatic dogs after administration of a combination of drugs acting on monoaminergic and cholinergic systems.
Mignot E,
Nishino S, Sharp LH, Arrigoni J, Siegel JM, Reid MS, Edgar DM, Ciaranello RD, Dement WC.
J Neurosci.
1993;
13
(3):
1057-64
-
Dopamine D2 mechanisms in canine narcolepsy.
Nishino S,
Arrigoni J, Valtier D, Miller JD, Guilleminault C, Dement WC, Mignot E.
J Neurosci.
1991;
11
(9):
2666-71
-
Effects of SDZ NVI-085, a putative subtype-selective alpha 1-agonist, on canine cataplexy, a disorder of rapid eye movement sleep.
Renaud A,
Nishino S, Dement WC, Guilleminault C, Mignot E.
Eur J Pharmacol.
1991;
205
(1):
11-6
-
Platelet alpha 2 adrenoceptors in human and canine narcolepsy.
Valtier D,
Nishino S, Guilleminault C, Dement WC, Mignot E.
Biol Psychiatry.
1991;
29
(4):
376-82
-
Effects of central alpha-2 adrenergic compounds on canine narcolepsy, a disorder of rapid eye movement sleep.
Nishino S,
Haak L, Shepherd H, Guilleminault C, Sakai T, Dement WC, Mignot E.
J Pharmacol Exp Ther.
1990;
253
(3):
1145-52
-
Prostaglandin E2 levels in cerebrospinal fluid of normal and narcoleptic dogs.
Nishino S,
Mignot E, Kilduff TS, Sakai T, Hayaishi O, Dement WC.
Biol Psychiatry.
1990;
28
(10):
904-10
-
Canine narcolepsy is associated with an elevated number of alpha 2-receptors in the locus coeruleus.
Fruhstorfer B,
Mignot E, Bowersox S, Nishino S, Dement WC, Guilleminault C.
Brain Res.
1989;
500
(1-2):
209-14
-
Central alpha 1 adrenoceptor subtypes in narcolepsy-cataplexy: a disorder of REM sleep.
Mignot E,
Guilleminault C, Bowersox S, Frusthofer B, Nishino S, Maddaluno J, Ciaranello R, Dement WC.
Brain Res.
1989;
490
(1):
186-91
-
Prostaglandin E2 and its methyl ester reduce cataplexy in canine narcolepsy.
Nishino S,
Mignot E, Fruhstorfer B, Dement WC, Hayaishi O.
Proc Natl Acad Sci U S A.
1989;
86
(7):
2483-7
Navigation for This Section: Psychiatry
Find a Researcher
Help
Internal Staff Login